NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its earnings results on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company had revenue of $3.92 million for the quarter, compared to analyst estimates of $3.23 million. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued 1-year price targets for Kalvista Pharmaceuticals' stock. Their forecasts range from $28.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 69.0% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Media coverage about KALV stock has been trending positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 877,600 shares, an increase of 11.3% from the December 15th total of 788,700 shares. Based on an average daily volume of 154,400 shares, the short-interest ratio is presently 5.7 days. Approximately 7.0% of the company's stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include NextCure (NXTC), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), ZEALAND PHARMA/S (ZEAL), Karyopharm Therapeutics (KPTI), Portola Pharmaceuticals (PTLA), Dermira (DERM), IGM Biosciences (IGMS), Phibro Animal Health (PAHC), Revance Therapeutics (RVNC), XBiotech (XBIT), RAPT Therapeutics (RAPT) and Opko Health (OPK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), BIOLINERX LTD/S (BLRX), Progenics Pharmaceuticals (PGNX) and SCYNEXIS (SCYX).

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $17.75.

Kalvista Pharmaceuticals has a market capitalization of $316.55 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]